CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors.
Damiano CarusoMichela PoliciMaria RinzivilloMarta ZerunianIlaria NacciMatteo MarascoLudovica MagiMariarita TaralloSimona GargiuloElsa IannicelliBruno AnnibaleAndrea LaghiFrancesco PanzutoPublished in: La Radiologia medica (2022)
In patients affected by metastatic NETs eligible for Everolimus treatment, radiomics could be used as imaging biomarker able to predict PFS and death.
Keyphrases
- neuroendocrine tumors
- end stage renal disease
- squamous cell carcinoma
- small cell lung cancer
- contrast enhanced
- ejection fraction
- lymph node metastasis
- chronic kidney disease
- newly diagnosed
- computed tomography
- high resolution
- peritoneal dialysis
- prognostic factors
- image quality
- patient reported outcomes
- fluorescence imaging